stockrow
Friday 6 November 2026
Export EBS’s income statement to Excel — free account
Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024.
- Revenue
- −52.4%
- EPS
- −166.4%
- Free cash flow
- +1,893.0%
- Total debt
- −23.4%
Quarter to September 2026, against a year earlier
5.92
0.02
+0.34%
Follow EBS
Alert me
Emergent Biosolutions Inc. (EBS) P/E ratio
Emergent Biosolutions Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 738× (November 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 13.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 10.0× | (35.24%) |
| FY2020 | 15.5× | (69.54%) |
| FY2019 | 50.9× | 7.32% |
| FY2018 | 47.4× | 92.78% |
| FY2017 | 24.6× | (14.87%) |
| FY2016 | 28.9× | 15.55% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 13.0× | 107.99% |
| 43 more quarters | Free account |
Against its own ten years
Low 0.0×
High 738×
Ten-year median
17.2×
Current reading's percentile
28
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. | n/m |
| SIGA Siga Technologies Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| BIOA BioAge Labs, Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| LFCR Lifecore Biomedical, Inc. compare | n/m |
| KMDA Kamada Ltd. compare | 18.1× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)